Cost-effectiveness of Intravitreous Ranibizumab vs Panretinal Photocoagulation

This secondary analysis of a randomized clinical trial evaluates incremental cost-effectiveness ratios of 0.5-mg ranibizumab therapy vs PRP for PDR.
Source: JAMA Ophthalmology - Category: Opthalmology Source Type: research